Tirzepatide
Dual GIP/GLP-1 receptor agonist studied for metabolic regulation and body weight research.
Molecular reference
Research background
Tirzepatide is a dual GIP and GLP-1 receptor agonist studied for its effects on glucose homeostasis and body weight regulation in research models. As a twincretin, it activates two complementary incretin pathways simultaneously.
Research has investigated its effects on insulin secretion, glucagon suppression, gastric emptying, and appetite regulation. It represents a significant advancement in the study of incretin-based metabolic therapies.
Summarizes published preclinical literature. Provided for research reference only; not a claim of efficacy or a description of human use.
Reconstitution
- Supplied as a lyophilized (freeze-dried) powder for laboratory reconstitution.
- Bacteriostatic water (0.9% benzyl alcohol) is the most common reconstitution solvent for multi-use research handling; sterile or acetic-acid solutions are used for specific compounds.
- Introduce solvent slowly against the vial wall rather than directly onto the powder, and allow it to dissolve without vigorous shaking.
- Use the reconstitution calculator to determine solvent volume for a target concentration in your protocol.
Storage & handling
- Lyophilized powder: store sealed at -20 °C for long-term stability; short periods at 2–8 °C are generally acceptable.
- Once reconstituted: refrigerate at 2–8 °C and protect from light; use within the compound-specific window noted on the COA.
- Avoid repeated freeze–thaw cycles of reconstituted solution.
- Keep away from direct light and heat at all times.
Purity & verification
Every Popular Peptides batch is third-party tested by HPLC and LC-MS with a published Certificate of Analysis (≥99% purity).
Related compounds
Tirzepatide is sold strictly as a research chemical for in-vitro laboratory and research use only. It is not intended for human or animal consumption, diagnostic, or therapeutic use. This page is educational reference information, not medical or usage guidance.